Fluidigm Corporation (NASDAQ:FLDM), an innovative biotechnology
tools provider with a vision to improve life through comprehensive
health insight, today announced that Imaging Mass Cytometry™ (IMC™)
is being utilized in studies led by researchers at Weill Cornell
Medicine to identify molecular links between African ancestry and
aggressive forms of breast and prostate cancer and investigate
these as a source of racial disparities in cancer outcomes.
The studies, Links between Ancestry and Outcome Disparity in
Breast and Prostate Cancer Patients Across the African Diaspora in
New York City, and Novel Complex Structural Variants and Epigenetic
Alterations Link Genomes of Prostate Cancer in African Americans
with Outcome Disparity, are funded by the New York Genome Center’s
Polyethnic-1000 initiative and the Department of Defense office of
Congressionally Directed Medical Research Programs, (CDMRP),
respectively. Weill Cornell Medicine researchers, as well as
those from collaborating institutions, are conducting these
studies.
The mission of the Polyethnic-1000 initiative is to deepen
understanding of the contributions ethnicities make to the
incidence and behavior of cancers, thereby improving outcomes,
especially for those who currently lack access to the most recent
advances in medical science. The program seeks to bring genomic
innovation to patient populations that are generally
under-represented in research. Polyethnic-1000 is a
multi-institutional network of collaborators throughout New York
City and beyond, including scientists, pathologists, institutional
review boards and administrators.
“While the focus for the Polyethnic-1000 and other initiatives
has been genomic-based studies, the team felt that the addition of
a proteomics approach could yield invaluable insights about ways in
which cancer is prevented, diagnosed and treated in this
population,” said Juan Miguel Mosquera, MD, MSc, Director of
Research Pathology at the Englander Institute for Precision
Medicine and Professor of Pathology and Laboratory
Medicine at Weill Cornell Medicine, a lead researcher of the
studies. “Integrative analyses of genomic data with CyTOF® data may
enable new discoveries regarding the structure of disease tissue at
the single-cell level, including the role of immune cells.”
Fluidigm® CyTOF technology is the basis for Imaging Mass
Cytometry, which is used in the company’s Hyperion™ Imaging
System.
Olivier Elemento, PhD, Director of the Englander Institute for
Precision Medicine and Professor of Physiology and Biophysics at
Weill Cornell Medicine, added, “The unique spatial aspects of
Imaging Mass Cytometry on the Hyperion Imaging System may
offer deep insights into the mechanisms of disease progression that
make it suitable for these important studies.”
The Polyethnic-1000 initiative is also funding projects
investigating pancreatic and lung cancer in Asian American patients
and the role of ethnicity in bladder cancer, as well as studies in
endometrial, urothelial and multiple myeloma in African Americans.
A study of colorectal cancer in African Americans may also include
research performed with the Hyperion Imaging System.
Black Americans have the highest death rate of any racial group
for most cancers. More than 70,000 African Americans die of cancer
each year.
“Collaborative efforts such as the Polyethnic-1000 and
CDMRP initiatives are essential to finding solutions to global
human health issues,” said Chris
Linthwaite, Fluidigm President and CEO. “Racial and
ethnic disparity in cancer is an important issue to address through
comprehensive scientific inquiry that can provide insights into new
approaches to prevention and treatment.
“Combining the high-parameter imaging capabilities of Imaging
Mass Cytometry with genomic research can be powerful, and we are
pleased that the researchers have chosen the Hyperion Imaging
System as a core tool in their efforts to seek insights that may
lead to answers.”
Findings from the projects will be shared with the research
community. Data will be stored in a repository maintained by the
New York Genome Center that will serve as a global resource for
efforts to understand the roles of ethnic diversity in cancer.
About FluidigmFluidigm (Nasdaq:FLDM)
focuses on the most pressing needs in translational and clinical
research, including cancer, immunology, and immunotherapy. Using
proprietary CyTOF and microfluidics technologies, we develop,
manufacture, and market multi-omic solutions to drive meaningful
insights in health and disease, identify biomarkers to inform
decisions, and accelerate the development of more effective
therapies. Our customers are leading academic, government,
pharmaceutical, biotechnology, plant and animal research, and
clinical laboratories worldwide. Together with them, we strive to
increase the quality of life for all. For more information,
visit fluidigm.com.
Fluidigm, the Fluidigm logo, CyTOF, Hyperion, Imaging
Mass Cytometry, and IMC are trademarks and/or registered trademarks
of Fluidigm Corporation or its affiliates in the
United States and/or other countries. All other
trademarks are the sole property of their respective owners.
Fluidigm products are provided for Research Use
Only. Not for use in diagnostic procedures.
Forward-Looking StatementsThis press release
contains forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995, including, among
others, statements regarding the potential benefits of research
conducted using Fluidigm technology and products. Forward-looking
statements are subject to numerous risks and uncertainties that
could cause actual results to differ materially from currently
anticipated results, including but not limited to risks relating to
challenges inherent in developing, manufacturing, launching,
marketing, and selling new products; potential product performance
and quality issues; intellectual property risks; competition;
uncertainties in contractual relationships; and reductions in
research and development spending or changes in budget priorities
by customers. Information on these and additional risks and
uncertainties and other information affecting Fluidigm business and
operating results is contained in Fluidigm’s Annual Report on Form
10-K for the year ended December 31, 2020, and in its other filings
with the Securities and Exchange Commission. These forward-looking
statements speak only as of the date hereof. Fluidigm disclaims any
obligation to update these forward-looking statements except as may
be required by law.
Available InformationWe use our website
(fluidigm.com), investor site (investors.fluidigm.com), corporate
Twitter account (@fluidigm), Facebook page (facebook.com/Fluidigm),
and LinkedIn page (linkedin.com/company/fluidigm-corporation) as
channels of distribution of information about our products, our
planned financial and other announcements, our attendance at
upcoming investor and industry conferences, and other matters. Such
information may be deemed material information, and we may use
these channels to comply with our disclosure obligations under
Regulation FD. Therefore, investors should monitor our website and
our social media accounts in addition to following our press
releases, SEC filings, public conference calls, and
webcasts.
Fluidigm
Media:Mark SpearmanSenior Director, Corporate
Communications650 243 6621mark.spearman@fluidigm.com
Investors:Peter DeNardo415 389
6400ir@fluidigm.com
Fluidigm (NASDAQ:FLDM)
Historical Stock Chart
From Mar 2024 to Apr 2024
Fluidigm (NASDAQ:FLDM)
Historical Stock Chart
From Apr 2023 to Apr 2024